Pharma Journalist -

Horizon Discovery Group plc announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon's proprietary…
Read More...

DNAnexus announced the availability of its Clinical Trial Solution (CTS) which streamlines the use of next-generation sequencing (NGS) data in regulated clinical trials. The company…
Read More...

Applied Therapeutics announced initiation of a Phase 1 clinical trial for AT-001, an oral small molecule in development for diabetic complications. The Phase 1 clinical trial is a…
Read More...

Teva Pharmaceutical announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of…
Read More...

LakePharma announced the launch of the LakePharma MicroBiomanufacturing (GMP) Center in Hopkinton, MA. Located at 35 South Street, the newly-acquired 69,000-square foot building…
Read More...

Mikhail Kalinichev, Director of In Vivo Neurology at Ipsen will be joining SMi's Pain Therapeutics Conference speaker panel and cover the topic of Therapeutic Application of Botulinum…
Read More...

Microbiome Invest in London on the 23rdof May has an international panel of experts discussing key topics such as the upcoming microbiome trigger points and technologies to watch, the…
Read More...

Join a huge community of ADC specialists at the Antibodies & Antibody Drug Conjugates conference this April 9th - 10th, Copthorne Tara Hotel, London. Now in its 6th year with a…
Read More...

ProBioGen announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial…
Read More...

Results from the Phase 1/2 trial (NEO1) and its ongoing extension study (NEO-EXT) show consistent safety data for Sanofi’s investigational avalglucosidase alfa (neoGAA) in patients with…
Read More...